Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Abstract
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine...
Paper Details
Title
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Published Date
Feb 12, 2015
Volume
372
Issue
7
Pages
621 - 630
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History